AR118601A2 - STABLE SOLID FORMULATIONS OF A GC-C RECEPTOR, POLYPEPTIDIC AGONIST SUITABLE FOR ORAL ADMINISTRATION - Google Patents
STABLE SOLID FORMULATIONS OF A GC-C RECEPTOR, POLYPEPTIDIC AGONIST SUITABLE FOR ORAL ADMINISTRATIONInfo
- Publication number
- AR118601A2 AR118601A2 ARP200100962A ARP200100962A AR118601A2 AR 118601 A2 AR118601 A2 AR 118601A2 AR P200100962 A ARP200100962 A AR P200100962A AR P200100962 A ARP200100962 A AR P200100962A AR 118601 A2 AR118601 A2 AR 118601A2
- Authority
- AR
- Argentina
- Prior art keywords
- cys
- oral administration
- formulations
- linaclotide
- stable solid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000007787 solid Substances 0.000 title abstract 2
- 102000000820 Enterotoxin Receptors Human genes 0.000 title 1
- 108010001687 Enterotoxin Receptors Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 4
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 abstract 3
- 108010024409 linaclotide Proteins 0.000 abstract 3
- 229960000812 linaclotide Drugs 0.000 abstract 3
- PLTGTJAZQRGMPP-FXQIFTODSA-N Asn-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O PLTGTJAZQRGMPP-FXQIFTODSA-N 0.000 abstract 1
- ISWAQPWFWKGCAL-ACZMJKKPSA-N Cys-Cys-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O ISWAQPWFWKGCAL-ACZMJKKPSA-N 0.000 abstract 1
- ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 abstract 1
- CGDZGRLRXPNCOC-SRVKXCTJSA-N Tyr-Cys-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CGDZGRLRXPNCOC-SRVKXCTJSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 108010010430 asparagine-proline-alanine Proteins 0.000 abstract 1
- 108010069495 cysteinyltyrosine Proteins 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02W—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO WASTEWATER TREATMENT OR WASTE MANAGEMENT
- Y02W90/00—Enabling technologies or technologies with a potential or indirect contribution to greenhouse gas [GHG] emissions mitigation
- Y02W90/10—Bio-packaging, e.g. packing containers made from renewable resources or bio-plastics
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen en la presente formulaciones sólidas estables de linaclotida adecuadas para la administración oral así como métodos para preparar dichas formulaciones. Las formulaciones descritas en la presente contienen un polipéptido que consiste de la secuencia de aminoácidos Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (linaclotida) o una de sus sales farmacéuticamente aceptables. Las formulaciones de linaclotida descritas en la presente son estables y tienen suficiente vida de depósito para fabricar, almacenar y distribuir el fármaco.Stable solid formulations of linaclotide suitable for oral administration as well as methods for preparing such formulations are described herein. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr ("linaclotide") or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have sufficient shelf life to manufacture, store, and distribute the drug.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8942208P | 2008-08-15 | 2008-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118601A2 true AR118601A2 (en) | 2021-10-20 |
Family
ID=56267523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100962A AR118601A2 (en) | 2008-08-15 | 2020-04-06 | STABLE SOLID FORMULATIONS OF A GC-C RECEPTOR, POLYPEPTIDIC AGONIST SUITABLE FOR ORAL ADMINISTRATION |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR118601A2 (en) |
| UA (1) | UA104870C2 (en) |
-
2009
- 2009-08-14 UA UAA201103016A patent/UA104870C2/en unknown
-
2020
- 2020-04-06 AR ARP200100962A patent/AR118601A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA104870C2 (en) | 2014-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6351746A2 (en) | STABLE SOLID FORMULATION OF A GC-C RECEIVER AGONIST POLYPEPTIDE FOR ORAL ADMINISTRATION | |
| CY1119243T1 (en) | VEGF COMPONENT PHARMACEUTICAL FORMS | |
| TW200637615A (en) | Therapeutic peptide formulations with improved stability | |
| MX2010007150A (en) | Recombinant vwf formulations. | |
| MX2009004147A (en) | PEPTIDE VACCINES FOR CANCERES THAT EXPRESS MPHOSPH1 OR DEPDC1 POLYPEPTIDES. | |
| MX2011011772A (en) | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies. | |
| WO2010027405A3 (en) | Formulations of gc-c receptor agonist polypeptides | |
| AR078950A1 (en) | PEPTIDE AGONIST OF GUANILATE CYCLASE C (GC-C) USEFUL FOR TREATMENTS OF GASTROINTESTINAL DISORDERS | |
| PE20080397A1 (en) | FUSION PROTEINS OF THE RECEIVER OF ADVANCED GLICATION FINAL PRODUCTS (RAGEPOR ITS ACRONYM IN ENGLISH), FORMULATIONS, AND METHODS OF USE OF THE SAME | |
| WO2009158704A3 (en) | Therapeutic agents comprising elastin-like peptides | |
| AR087070A1 (en) | RELAXINE RELEASING FUSION PROTEINS AND USES OF THE SAME | |
| JP2013518115A5 (en) | ||
| PH12014501642B1 (en) | Peptide vaccines for cancers expressing tumor-associated antigens | |
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| NZ621868A (en) | Growth hormone polypeptides and methods of making and using same | |
| WO2009025196A1 (en) | Foxm1 peptide and medicinal agent comprising the same | |
| PE20142332A1 (en) | METHOD AND FORMULATION TO REDUCE THE AGGREGATION OF A MACROMOLECLE UNDER PHYSIOLOGICAL CONDITIONS | |
| CY1118057T1 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | |
| JP2016501866A (en) | Peptides that stimulate subcutaneous adipogenesis | |
| AR088727A1 (en) | CYCLE PEPTIDES WITH ANTINEOPLASIC AND ANTIANGIOGEN ACTIVITY | |
| ZA200807027B (en) | Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | |
| WO2009064366A3 (en) | Methods and compositions for protein labeling using lipoic acid ligases | |
| AR118601A2 (en) | STABLE SOLID FORMULATIONS OF A GC-C RECEPTOR, POLYPEPTIDIC AGONIST SUITABLE FOR ORAL ADMINISTRATION | |
| UY32054A (en) | STABLE SOLID FORMULATION OF A GC-C RECEIVER AGONIST POLYPEPTIDE FOR ORAL ADMINISTRATION. | |
| ECSP11010897A (en) | STABLE SOLID FORMULATION OF A RECEPTOR AGONIST POLYPEPTIDE |